New HIV combo shot shows promise in early trial

NCT ID NCT05996471

First seen Jan 11, 2026 · Last updated May 07, 2026 · Updated 13 times

Summary

This study tests a new drug combination (VH3810109 plus cabotegravir) for adults with HIV whose virus is already well-controlled by standard medication. The goal is to see if this new approach can keep the virus suppressed as effectively as current treatments. About 185 participants will receive either the new combination or standard care, and researchers will monitor viral levels and side effects over six months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • GSK Investigational Site

    Birmingham, Alabama, 35222, United States

  • GSK Investigational Site

    Bakersfield, California, 93301, United States

  • GSK Investigational Site

    Los Angeles, California, 90027, United States

  • GSK Investigational Site

    Los Angeles, California, 90069, United States

  • GSK Investigational Site

    Palm Springs, California, 92262, United States

  • GSK Investigational Site

    Sacramento, California, 95825, United States

  • GSK Investigational Site

    San Francisco, California, 94110, United States

  • GSK Investigational Site

    New Haven, Connecticut, 06510, United States

  • GSK Investigational Site

    Washington D.C., District of Columbia, 20007, United States

  • GSK Investigational Site

    Washington D.C., District of Columbia, 20037, United States

  • GSK Investigational Site

    Fort Lauderdale, Florida, 33308, United States

  • GSK Investigational Site

    Ft. Pierce, Florida, 34982, United States

  • GSK Investigational Site

    Miami, Florida, 33133, United States

  • GSK Investigational Site

    Orlando, Florida, 32803, United States

  • GSK Investigational Site

    Pensacola, Florida, 32503, United States

  • GSK Investigational Site

    Sarasota, Florida, 34237, United States

  • GSK Investigational Site

    Vero Beach, Florida, 32960, United States

  • GSK Investigational Site

    West Palm Beach, Florida, 33409, United States

  • GSK Investigational Site

    Decatur, Georgia, 30033, United States

  • GSK Investigational Site

    Chicago, Illinois, 60611, United States

  • GSK Investigational Site

    Boston, Massachusetts, 02115, United States

  • GSK Investigational Site

    Springfield, Massachusetts, 01105, United States

  • GSK Investigational Site

    Southfield, Michigan, 48075, United States

  • GSK Investigational Site

    Columbia, Missouri, 65212, United States

  • GSK Investigational Site

    Newark, New Jersey, 07102, United States

  • GSK Investigational Site

    Albuquerque, New Mexico, 87109, United States

  • GSK Investigational Site

    Santa Fe, New Mexico, 87505, United States

  • GSK Investigational Site

    Manhasset, New York, 11030, United States

  • GSK Investigational Site

    New York, New York, 10029, United States

  • GSK Investigational Site

    New York, New York, 10032, United States

  • GSK Investigational Site

    New York, New York, 10461, United States

  • GSK Investigational Site

    The Bronx, New York, 10467, United States

  • GSK Investigational Site

    Greensboro, North Carolina, 27401-1209, United States

  • GSK Investigational Site

    Cincinnati, Ohio, 45267, United States

  • GSK Investigational Site

    Portland, Oregon, 97239, United States

  • GSK Investigational Site

    Philadelphia, Pennsylvania, 19104, United States

  • GSK Investigational Site

    Nashville, Tennessee, 37208, United States

  • GSK Investigational Site

    Austin, Texas, 78705, United States

  • GSK Investigational Site

    Dallas, Texas, 75246, United States

  • GSK Investigational Site

    El Paso, Texas, 79902, United States

  • GSK Investigational Site

    Houston, Texas, 77030, United States

  • GSK Investigational Site

    Houston, Texas, 77098, United States

  • GSK Investigational Site

    Watertown, Wisconsin, 53226, United States

  • GSK Investigational Site

    San Juan, 00909, Puerto Rico

  • GSK Investigational Site

    San Juan, 909, Puerto Rico

Conditions

Explore the condition pages connected to this study.